Document Detail

Attenuated methamphetamine-induced locomotor sensitization in serotonin transporter knockout mice is restored by serotonin 1B receptor antagonist treatment.
MedLine Citation:
PMID:  25485646     Owner:  NLM     Status:  Publisher    
Repeated administration of methamphetamine (METH) enhances acute locomotor responses to METH administered in the same context, a phenomenon termed as 'locomotor sensitization'. Although many of the acute effects of METH are mediated by its influences on the compartmentalization of dopamine, serotonin systems have also been suggested to influence the behavioral effects of METH in ways that are not fully understood. The present experiments examined serotonergic roles in METH-induced locomotor sensitization by assessing: (a) the effect of serotonin transporter (SERT; Slc6A4) knockout (KO) on METH-induced locomotor sensitization; (b) extracellular monoamine levels in METH-treated animals as determined by in-vivo microdialysis; and (c) effects of serotonin (5-HT) receptor antagonists on METH-induced behavioral sensitization, with focus on effects of the 5-HT1B receptor antagonist SB 216641 and a comparison with the 5-HT2 receptor antagonist ketanserin. Repeated METH administration failed to induce behavioral sensitization in homozygous SERT KO (SERT-/-) mice under conditions that produced substantial sensitization in wild-type or heterozygous SERT KO (SERT+/-) mice. The selective 5-HT1B antagonist receptor SB 216641 restored METH-induced locomotor sensitization in SERT-/- mice, whereas ketanserin was ineffective. METH-induced increases in extracellular 5-HT (5-HTex) levels were substantially reduced in SERT-/- mice, although SERT genotype had no effect on METH-induced increases in extracellular dopamine. These experiments demonstrate that 5-HT actions, including those at 5-HT1B receptors, contribute to METH-induced locomotor sensitization. Modulation of 5-HT1B receptors might aid therapeutic approaches to the sequelae of chronic METH use.
Moe Igari; Hao-Wei Shen; Yoko Hagino; Setsu Fukushima; Yoshiyuki Kasahara; Klaus-Peter Lesch; Dennis L Murphy; Frank Scott Hall; George R Uhl; Kazutaka Ikeda; Nobuo Yaegashi; Ichiro Sora
Related Documents :
20718616 - Roxatidine, an h(2) receptor blocker, is an estrogenic compound--experimental evidence.
3023306 - Human mammary cancer cell mutants with altered hormone receptor activity.
14568026 - Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampu...
7526296 - [3h]rolipram binding and phosphodiesterase activity in neuroblastoma n18tg-2 and glioma...
19217356 - N-methyl-d-aspartate receptors in the insular cortex modulate baroreflex in unanestheti...
21163296 - Additive effects of cannabinoid cb1 receptors blockade and cholecystokinin on feeding i...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-12-5
Journal Detail:
Title:  Behavioural pharmacology     Volume:  -     ISSN:  1473-5849     ISO Abbreviation:  Behav Pharmacol     Publication Date:  2014 Dec 
Date Detail:
Created Date:  2014-12-8     Completed Date:  -     Revised Date:  2014-12-9    
Medline Journal Info:
Nlm Unique ID:  9013016     Medline TA:  Behav Pharmacol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotin...
Next Document:  Eating high fat chow, but not drinking sucrose or saccharin, enhances the development of sensitizati...